Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 16;14(7):869.
doi: 10.3390/antiox14070869.

Inhaled and Systemic Steroids for Bronchopulmonary Dysplasia: Targeting Inflammation and Oxidative Stress

Affiliations
Review

Inhaled and Systemic Steroids for Bronchopulmonary Dysplasia: Targeting Inflammation and Oxidative Stress

Francesca Galletta et al. Antioxidants (Basel). .

Abstract

Bronchopulmonary dysplasia (BPD) remains a significant complication of preterm birth, characterized by impaired alveolar and vascular development, chronic lung inflammation, and long-term respiratory morbidity. Corticosteroids, both systemic and inhaled, have been widely investigated as potential therapeutic agents due to their anti-inflammatory properties and their emerging role in modulating oxidative stress. This narrative review explores the current evidence regarding the use of inhaled and systemic corticosteroids in the prevention and management of BPD, analyzing their efficacy, safety profiles, and long-term outcomes. While systemic corticosteroids, particularly dexamethasone, have demonstrated benefits in reducing ventilator dependence and lung inflammation, concerns regarding adverse neurodevelopmental effects have limited their routine use. Inhaled steroids have been proposed as a safer alternative, but their role in altering the disease trajectory remains controversial. A better understanding of the optimal timing, dosage, and patient selection is essential to maximize benefits while minimizing risks. Future research should focus on optimizing dosing strategies and identifying subgroups of preterm infants who may derive the greatest benefit from corticosteroid therapy.

Keywords: bronchopulmonary dysplasia; inflammation; inhaled steroids; lung injury; newborn; oxidative stress; systemic steroids.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Conceptual model illustrating the proposed role of oxidative stress and inflammation in the pathogenesis of bronchopulmonary dysplasia (BPD) and the potential modulatory effects of corticosteroids. The diagram integrates current knowledge from experimental and clinical studies to depict how antenatal and postnatal factors trigger reactive oxygen species (ROS) production and pro-inflammatory cascades, contributing to lung injury and impaired alveolar development. Corticosteroids are shown to act at multiple levels, modulating inflammation and oxidative stress pathways.

Similar articles

References

    1. Jensen E.A., Dysart K., Gantz M.G., McDonald S., Bamat N.A., Keszler M., Kirpalani H., Laughon M.M., Poindexter B.B., Duncan A.F., et al. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am. J. Respir. Crit. Care Med. 2019;200:751–759. doi: 10.1164/rccm.201812-2348OC. - DOI - PMC - PubMed
    1. Siffel C., Kistler K.D., Lewis J.F.M., Sarda S.P. Global incidence of bronchopulmonary dysplasia among extremely preterm infants: A systematic literature review. J. Matern. Fetal Neonatal Med. 2021;34:1721–1731. doi: 10.1080/14767058.2019.1646240. - DOI - PubMed
    1. Higgins R.D., Jobe A.H., Koso-Thomas M., Bancalari E., Viscardi R.M., Hartert T.V., Ryan R.M., Kallapur S.G., Steinhorn R.H., Konduri G.G., et al. Bronchopulmonary dysplasia: Executive summary of a workshop. J. Pediatr. 2018;197:300–308. doi: 10.1016/j.jpeds.2018.01.043. - DOI - PMC - PubMed
    1. Strashun S., Seliga-Siwecka J., Chioma R., Zielińska K., Włodarczyk K., Villamor E., Philip R.K., Assaf N.A., Pierro M. Steroid use for established bronchopulmonary dysplasia: Study protocol for a systematic review and meta-analysis. BMJ Open. 2022;12:e059553. doi: 10.1136/bmjopen-2021-059553. - DOI - PMC - PubMed
    1. Martin R.J., Di Fiore J.M., Walsh M.C. Hypoxic Episodes in Bronchopulmonary Dysplasia. Clin. Perinatol. 2015;42:825–838. doi: 10.1016/j.clp.2015.08.009. - DOI - PMC - PubMed

LinkOut - more resources